IRCT20200105046010N1招募中未知
In- Vivo Bioequivalence study of Levetiracetam tablet 1000mg Cobel Darou (LEVEBEL 1000mg) with brand drugs (KEPPRA 1000mg UCB Pharma, Belgium) in Iranian healthy volunteers
Cobel Darou Pharmaceutical Company0 个研究点目标入组 24 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General health (liver & heart & kidney )
- •Body mass index (18-25)
- •Informed consent
- •Age (18-60 )
排除标准
- •A history of cardiovascular disease
- •A history of Liver & Kidney disease
- •Alcohol & Drug addiction
- •Hypersensitivity
研究者
相似试验
招募中
2 期
The effect of levetiracetam and phenobarbital on the control of neonatal seizuresIRCT20160523028008N23Hamedan University of Medical Sciences40
已完成
1 期
An Open-label, Bioequivalence Study to Evaluate LEV Administered as a 45-min Intravenous Infusion and Same Dosage LEV Oral Tablet in ChineseHuman VolunteersNCT01618903UCB Pharma24
已完成
不适用
Bioequivalency Study of Levetiracetam 1g Tablets Under Fed ConditionsSeizuresNCT00827320Roxane Laboratories26
已完成
不适用
Bioequivalency Study of Levetiracetam 1g Under Fasted ConditionsSeizuresNCT00826722Roxane Laboratories30
已完成
2 期
evetiractem for the prophylactic treatment of pediatric migrainemigraine headache.migraine without aura or clasic migraineIRCT2017021632603N1Vice chancellor for research, Tehran university of medical sciense68